Abivax SA (ABVX-FR): Remarkable data opens door to $15bn IBD market

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Published to the market and investors on 6th September 2018 @ 7am (London time).

Abivax SA (ABVX-FR): Remarkable data opens door to $15bn IBD market
Recommendation: OUTPERFORM
Target Price: EUR19.50
Current Price: EUR7.39 (COB on 4^th September 2018)

KEY TAKEAWAY

Phase 2a ulcerative colitis ("UC") data indicates real promise for the ABX-464 in the $15bn inflammatory bowel disease ("IBD") market. A small early stage trial, positive read-out on all key parameters suggests real benefits from this oral once a day drug for patients seeking to avoid repeated intravenous infusions or at worst surgical bowel removal. Already showing promise in the depletion of latent HIV reservoirs, these new data should significantly de-risk the drug's path to market potentially opening the door to an even larger opportunity in inflammatory disease. We reiterate both our OUTPERFORM recommendation and EUR19.50 target price.

Statistically significant benefits - Although still a limited duration (8 week) early trial performed in just 32 patients, the trial demonstrated statistically significant improvements over placebo in both mucosal healing (4.5x) as well as clinical status (3.2x) in patients' refractory to either steroids or second or third line infused biologic anti-TNF (tumour necrosis factor).

Outcomes compares well to current drugs - While one must exercise due caution extrapolating from small early trial results to late stage studies, the impact on healing and clinical outcomes compare well with and could exceed the benefits of marketed products particularly tofacitinib from Pfizer recently approved for used in steroid refractory patients.

Safe and well tolerated - This trial and those in HIV suggest that the drug is safe and well tolerated with no evidence of the infections frequently associated with the with anti-TNF antibodies or small molecule anti-inflammatory drugs like tofacitinib. While one patient in the current Phase 2b left the trial due to elevated liver enzymes, this is apparently common amongst patients with IBD and may not be linked to the drug.

Opportunity to meet unmet need in substantial market - While the combined ulcerative colitis and Crohn's disease amounts to around $15bn, significant numbers of patients are refractory to therapy. There is a substantial opportunity in IBD and potentially more broadly in the broad range of currently inadequately served inflammatory indications. Combining anti-inflammatory effects with viral reservoir depletion should also make the ABX-464 a more compelling proposition in HIV.

Further data and trials in prospect - First data showing a sustained response from the open extension element of the Phase 2a UC trial is due to report late October. A further dose ranging Phase 2b in UC is planned, as well as a trial in Crohn's disease.

Under-valued at current levels - Funded through Q1/2020E following a EUR20m debt financing secured in July 2018 and based on this encouraging study, the company looks well placed to generate significant additional data from the Phase 2b trials in UC and HIV. We reiterate both our OUTPERFORM recommendation and EUR19.50 target price.

Kind regards,

Chris Redhead | Analyst

goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | chris.redhead@goetzpartners.com / healthcareresearch@goetzpartners.com

www.goetzpartnerssecurities.com

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

Click here to see our privacy policy.

GPSL has a formal client relationship with Abivax SA.

GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation ("GDPR") - if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This e-mail (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, Research Tree, RNS Reach and Thomson Reuters.

Please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=59e6b263-f97f-4f50-8cc8-b86293c7f36a&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.